N. BILLERICA, Mass.--(BUSINESS WIRE)--Avista Capital Partners’ recently acquired medical imaging business (MI) reported today that the Food and Drug Administration (FDA) has granted pediatric exclusivity for studies conducted on Cardiolite® (Kit for the Preparation of Technetium Tc99m Sestamibi for Injection), effective January 8, 2008, under Section 505A of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355a) as amended by the Best Pharmaceuticals for Children Act (BPCA). This grant extends the marketing exclusivity of Cardiolite for an additional six months beyond patent expiration on January 29, 2008.
